Detalhe da pesquisa
1.
An integrated suite of modeling tools that empower scientists in structure- and property-based drug design.
J Comput Aided Mol Des
; 29(6): 511-23, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25921252
2.
A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Bioorg Med Chem Lett
; 23(18): 5097-104, 2013 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23932790
3.
Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors.
Elife
; 122023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36975198
4.
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
Bioorg Med Chem Lett
; 22(24): 7627-33, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23107482
5.
Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310.
J Med Chem
; 64(6): 2953-2966, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33682420
6.
Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.
Bioorg Med Chem Lett
; 20(7): 2229-33, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20189383
7.
Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain.
J Med Chem
; 62(8): 4091-4109, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943032
8.
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells.
ACS Med Chem Lett
; 7(3): 223-8, 2016 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26985305
9.
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.
ACS Med Chem Lett
; 7(6): 595-600, 2016 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27326333
10.
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
ACS Chem Biol
; 11(10): 2897-2907, 2016 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27571029
11.
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.
ACS Med Chem Lett
; 5(6): 662-7, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24944740
12.
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.
ACS Med Chem Lett
; 4(1): 103-7, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900569
13.
Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
J Med Chem
; 56(11): 4764-85, 2013 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-23659214
14.
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.
J Med Chem
; 55(24): 10958-71, 2012 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-23199076
15.
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
J Med Chem
; 55(13): 6176-93, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22698084
16.
Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
J Med Chem
; 54(9): 3426-35, 2011 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21495671